AMG510 is a KRAS-targeted drug mainly used to treat patients with advanced non-small cell lung cancer with KRAS-G12C mutation.
KRAS gene is one of the RAS genes, and KRAS gene mutation will cause tumor cells to proliferate and divide uncontrollably, leading to cancer.
KRAS is a common oncogene, and KRAS gene mutations can be seen in about 90% of pancreatic cancers and 15-20% of lung cancers. the KRAS-G12C mutation is a specific sub-mutation that is most common in non-small cell lung cancer.
AMG510 has targeted anti-tumor activity against KRAS-G12C mutation.AMG510 can specifically bind to the KRAS-G12C mutation gene and inactivate it, resulting in tumor shrinkage and partial or complete remission in most patients.
Currently AMG510 is mainly used to treat patients with locally advanced or metastatic non-small cell lung adenocarcinoma with KRAS-G12C mutation. Adverse reactions such as decreased appetite, diarrhea, fatigue, hepatotoxicity may occur after use, and it is prohibited for patients with severe hepatic insufficiency, severe interstitial pneumonitis, etc. Therefore, it should be used according to the instruction of the doctor, and should not be used without authorization.
It is recommended that patients with advanced non-small cell lung cancer undergo genetic diagnosis, and if it meets the indications of AMG510, the drug can be used under the guidance of physicians.